Tag: obesity market

Market News

Novo Nordisk Faces Shareholder Lawsuit Over CagriSema Weight Loss Drug

Shareholders claim Novo Nordisk misled them about its next big weight-loss drug CagriSema before disappointing trial results tanked the stock....

29/07/2026

5 views

Read More

Market News

Zealand Pharma Stock Plunge: What Lies Ahead for Weight Loss Drugs

Zealand Pharma just endured its two worst days in over a decade as weight loss drug data disappointed investors. While...

19/06/2026

5 views

Read More

Market News

Novo Nordisk Q1 2026: Wegovy Pill Sales Surge Beats Forecasts- Deciding to use investment categories like Stocks and Market News due to financial content focus.

Novo Nordisk just posted impressive Q1 numbers with its Wegovy pill smashing sales forecasts in the US. The company raised...

11/05/2026

5 views

Read More

Market News

Novo Nordisk Struggles: GLP-1 Market Challenges 2026

Novo Nordisk's stock has crashed 75% from its peak amid fierce competition, pricing squeezes, and a disappointing pipeline trial. Is...

26/02/2026

9 views

Read More

Altcoins

Novo Nordisk Stock Drops After Weight Loss Drug Trial Miss

Novo Nordisk's stock took a sharp hit after its promising next-gen weight loss drug CagriSema fell short against Eli Lilly's...

23/02/2026

5 views

Read More

Growth Picks

Buy Eli Lilly: Top GLP-1 Leader Amid Rising Competition

With competition closing in on the booming GLP-1 space, one pharma giant stands out as the clear frontrunner according to...

20/02/2026

5 views

Read More

Growth Picks

Three Smart Winners Beyond the AI Boom

As markets obsess over AI hardware giants, overlooked quality names in payroll, consulting, and healthcare are quietly building lasting value—could...

09/02/2026

4 views

Read More

Stocks

Eli Lilly Surges Ahead in GLP-1 Market as Novo Faces 2026 Decline

While both giants face U.S. pricing squeezes on weight-loss drugs, Eli Lilly just forecasted massive 2026 growth while Novo Nordisk...

04/02/2026

17 views

Read More

Altcoins

Novo Nordisk GLP-1 Pill: Pricing Pressures & 2026 Outlook

At JPMorgan 2026, Novo Nordisk's CEO warned of major price pressure on GLP-1 drugs this year, even as their new...

14/01/2026

8 views

Read More

Global Companies

Zealand Pharma’s Bold 2030 Plan Shakes Weight Loss Race

While Novo Nordisk shares are down 50% in 2025 and investors flock to Eli Lilly, a smaller Danish player just...

11/12/2025

3 views

Read More